Selected research
Industry Research
GLP-1 Drug Peptide API Industry Research Report 2026
Market perspective
The global GLP-1 Drug Peptide API market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for GLP-1 Drug Peptide API is forecast to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for GLP-1 Drug Peptide API is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for GLP-1 Drug Peptide API is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of GLP-1 Drug Peptide API include , among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global GLP-1 Drug Peptide API market in revenue (US$ million) and, where applicable, sales volume (Tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of types and applications, harmonizes vendor attribution, and presents comparable time series by company, type, application, and region/country, including indicative price bands (US$/Tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for manufacturers, new entrants, channel partners, and investors; the report also reviews technology shifts and notable product introductions relevant to GLP-1 Drug Peptide API.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
GLP-1 Drug Peptide API Market by Company
CPC Scientific
Novo Nordisk
Teva Pharmaceutical Industries Ltd
HYBIO Pharmaceutical
JYMedtech
SINOPEP
Shengnuo Biotechnology
Suzhou Tianma Pharmaceutical
WuXi AppTec
Zhejiang Peptites Biotech
GLP-1 Drug Peptide API Segment by Type
Semaglutide
Liraglutide
Tilpotide
GLP-1 Drug Peptide API Segment by Application
Diabetes
Obesity
Other
GLP-1 Drug Peptide API Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GLP-1 Drug Peptide API market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of GLP-1 Drug Peptide API and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GLP-1 Drug Peptide API.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of GLP-1 Drug Peptide API manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of GLP-1 Drug Peptide API by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of GLP-1 Drug Peptide API in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Semaglutide
- Liraglutide
- Tilpotide
Applications
- Diabetes
- Obesity
- Other
Companies covered
- CPC Scientific
- Novo Nordisk
- Teva Pharmaceutical Industries Ltd
- HYBIO Pharmaceutical
- JYMedtech
- SINOPEP
- Shengnuo Biotechnology
- Suzhou Tianma Pharmaceutical
- WuXi AppTec
- Zhejiang Peptites Biotech
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 GLP-1 Drug Peptide API by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.2.2 Semaglutide
- 2.2.3 Liraglutide
- 2.2.4 Tilpotide
- 2.3 GLP-1 Drug Peptide API by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Diabetes
- 2.3.3 Obesity
- 2.3.4 Other
- 2.4 Global Market Growth Prospects
- 2.4.1 Global GLP-1 Drug Peptide API Production Value Estimates and Forecasts (2021-2032)
- 2.4.2 Global GLP-1 Drug Peptide API Production Capacity Estimates and Forecasts (2021-2032)
- 2.4.3 Global GLP-1 Drug Peptide API Production Estimates and Forecasts (2021-2032)
- 2.4.4 Global GLP-1 Drug Peptide API Market Average Price (2021-2032)
3 Market Competitive Landscape by Manufacturers
- 3.1 Global GLP-1 Drug Peptide API Production by Manufacturers (2021-2026)
- 3.2 Global GLP-1 Drug Peptide API Production Value by Manufacturers (2021-2026)
- 3.3 Global GLP-1 Drug Peptide API Average Price by Manufacturers (2021-2026)
- 3.4 Global GLP-1 Drug Peptide API Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global GLP-1 Drug Peptide API Key Manufacturers, Manufacturing Sites & Headquarters
- 3.6 Global GLP-1 Drug Peptide API Manufacturers, Product Type & Application
- 3.7 Global GLP-1 Drug Peptide API Manufacturers Established Date
- 3.8 Global GLP-1 Drug Peptide API Market CR5 and HHI
- 3.9 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 CPC Scientific
- 4.1.1 CPC Scientific GLP-1 Drug Peptide API Company Information
- 4.1.2 CPC Scientific GLP-1 Drug Peptide API Business Overview
- 4.1.3 CPC Scientific GLP-1 Drug Peptide API Production Capacity, Value and Gross Margin (2021-2026)
- 4.1.4 CPC Scientific Product Portfolio
- 4.1.5 CPC Scientific Recent Developments
- 4.2 Novo Nordisk
- 4.2.1 Novo Nordisk GLP-1 Drug Peptide API Company Information
- 4.2.2 Novo Nordisk GLP-1 Drug Peptide API Business Overview
- 4.2.3 Novo Nordisk GLP-1 Drug Peptide API Production Capacity, Value and Gross Margin (2021-2026)
- 4.2.4 Novo Nordisk Product Portfolio
- 4.2.5 Novo Nordisk Recent Developments
- 4.3 Teva Pharmaceutical Industries Ltd
- 4.3.1 Teva Pharmaceutical Industries Ltd GLP-1 Drug Peptide API Company Information
- 4.3.2 Teva Pharmaceutical Industries Ltd GLP-1 Drug Peptide API Business Overview
- 4.3.3 Teva Pharmaceutical Industries Ltd GLP-1 Drug Peptide API Production Capacity, Value and Gross Margin (2021-2026)
- 4.3.4 Teva Pharmaceutical Industries Ltd Product Portfolio
- 4.3.5 Teva Pharmaceutical Industries Ltd Recent Developments
- 4.4 HYBIO Pharmaceutical
- 4.4.1 HYBIO Pharmaceutical GLP-1 Drug Peptide API Company Information
- 4.4.2 HYBIO Pharmaceutical GLP-1 Drug Peptide API Business Overview
- 4.4.3 HYBIO Pharmaceutical GLP-1 Drug Peptide API Production Capacity, Value and Gross Margin (2021-2026)
- 4.4.4 HYBIO Pharmaceutical Product Portfolio
- 4.4.5 HYBIO Pharmaceutical Recent Developments
- 4.5 JYMedtech
- 4.5.1 JYMedtech GLP-1 Drug Peptide API Company Information
- 4.5.2 JYMedtech GLP-1 Drug Peptide API Business Overview
- 4.5.3 JYMedtech GLP-1 Drug Peptide API Production Capacity, Value and Gross Margin (2021-2026)
- 4.5.4 JYMedtech Product Portfolio
- 4.5.5 JYMedtech Recent Developments
- 4.6 SINOPEP
- 4.6.1 SINOPEP GLP-1 Drug Peptide API Company Information
- 4.6.2 SINOPEP GLP-1 Drug Peptide API Business Overview
- 4.6.3 SINOPEP GLP-1 Drug Peptide API Production Capacity, Value and Gross Margin (2021-2026)
- 4.6.4 SINOPEP Product Portfolio
- 4.6.5 SINOPEP Recent Developments
- 4.7 Shengnuo Biotechnology
- 4.7.1 Shengnuo Biotechnology GLP-1 Drug Peptide API Company Information
- 4.7.2 Shengnuo Biotechnology GLP-1 Drug Peptide API Business Overview
- 4.7.3 Shengnuo Biotechnology GLP-1 Drug Peptide API Production Capacity, Value and Gross Margin (2021-2026)
- 4.7.4 Shengnuo Biotechnology Product Portfolio
- 4.7.5 Shengnuo Biotechnology Recent Developments
- 4.8 Suzhou Tianma Pharmaceutical
- 4.8.1 Suzhou Tianma Pharmaceutical GLP-1 Drug Peptide API Company Information
- 4.8.2 Suzhou Tianma Pharmaceutical GLP-1 Drug Peptide API Business Overview
- 4.8.3 Suzhou Tianma Pharmaceutical GLP-1 Drug Peptide API Production Capacity, Value and Gross Margin (2021-2026)
- 4.8.4 Suzhou Tianma Pharmaceutical Product Portfolio
- 4.8.5 Suzhou Tianma Pharmaceutical Recent Developments
- 4.9 WuXi AppTec
- 4.9.1 WuXi AppTec GLP-1 Drug Peptide API Company Information
- 4.9.2 WuXi AppTec GLP-1 Drug Peptide API Business Overview
- 4.9.3 WuXi AppTec GLP-1 Drug Peptide API Production Capacity, Value and Gross Margin (2021-2026)
- 4.9.4 WuXi AppTec Product Portfolio
- 4.9.5 WuXi AppTec Recent Developments
- 4.10 Zhejiang Peptites Biotech
- 4.10.1 Zhejiang Peptites Biotech GLP-1 Drug Peptide API Company Information
- 4.10.2 Zhejiang Peptites Biotech GLP-1 Drug Peptide API Business Overview
- 4.10.3 Zhejiang Peptites Biotech GLP-1 Drug Peptide API Production Capacity, Value and Gross Margin (2021-2026)
- 4.10.4 Zhejiang Peptites Biotech Product Portfolio
- 4.10.5 Zhejiang Peptites Biotech Recent Developments
5 Global GLP-1 Drug Peptide API Production by Region
- 5.1 Global GLP-1 Drug Peptide API Production Estimates and Forecasts by Region: 2021 VS 2025 VS 2032
- 5.2 Global GLP-1 Drug Peptide API Production by Region: 2021-2032
- 5.2.1 Global GLP-1 Drug Peptide API Production by Region: 2021-2026
- 5.2.2 Global GLP-1 Drug Peptide API Production Forecast by Region (2027-2032)
- 5.3 Global GLP-1 Drug Peptide API Production Value Estimates and Forecasts by Region: 2021 VS 2025 VS 2032
- 5.4 Global GLP-1 Drug Peptide API Production Value by Region: 2021-2032
- 5.4.1 Global GLP-1 Drug Peptide API Production Value by Region: 2021-2026
- 5.4.2 Global GLP-1 Drug Peptide API Production Value Forecast by Region (2027-2032)
- 5.5 Global GLP-1 Drug Peptide API Market Price Analysis by Region (2021-2026)
- 5.6 Global GLP-1 Drug Peptide API Production and Value, YOY Growth
- 5.6.1 North America GLP-1 Drug Peptide API Production Value Estimates and Forecasts (2021-2032)
- 5.6.2 Europe GLP-1 Drug Peptide API Production Value Estimates and Forecasts (2021-2032)
- 5.6.3 China GLP-1 Drug Peptide API Production Value Estimates and Forecasts (2021-2032)
- 5.6.4 Japan GLP-1 Drug Peptide API Production Value Estimates and Forecasts (2021-2032)
6 Global GLP-1 Drug Peptide API Consumption by Region
- 6.1 Global GLP-1 Drug Peptide API Consumption Estimates and Forecasts by Region: 2021 VS 2025 VS 2032
- 6.2 Global GLP-1 Drug Peptide API Consumption by Region (2021-2032)
- 6.2.1 Global GLP-1 Drug Peptide API Consumption by Region: 2021-2026
- 6.2.2 Global GLP-1 Drug Peptide API Forecasted Consumption by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America GLP-1 Drug Peptide API Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America GLP-1 Drug Peptide API Consumption by Country (2021-2032)
- 6.3.3 United States
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe GLP-1 Drug Peptide API Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe GLP-1 Drug Peptide API Consumption by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Russia
- 6.4.8 Spain
- 6.4.9 Netherlands
- 6.4.10 Switzerland
- 6.4.11 Sweden
- 6.4.12 Poland
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific GLP-1 Drug Peptide API Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific GLP-1 Drug Peptide API Consumption by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 India
- 6.5.7 Australia
- 6.5.8 Taiwan
- 6.5.9 Southeast Asia
- 6.6 South America, Middle East & Africa
- 6.6.1 South America, Middle East & Africa GLP-1 Drug Peptide API Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East & Africa GLP-1 Drug Peptide API Consumption by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 Argentina
- 6.6.5 Chile
- 6.6.6 Turkey
- 6.6.7 GCC Countries
7 Segment by Type
- 7.1 Global GLP-1 Drug Peptide API Production by Type (2021-2032)
- 7.1.1 Global GLP-1 Drug Peptide API Production by Type (2021-2032) & (Tons)
- 7.1.2 Global GLP-1 Drug Peptide API Production Market Share by Type (2021-2032)
- 7.2 Global GLP-1 Drug Peptide API Production Value by Type (2021-2032)
- 7.2.1 Global GLP-1 Drug Peptide API Production Value by Type (2021-2032) & (US$ Million)
- 7.2.2 Global GLP-1 Drug Peptide API Production Value Market Share by Type (2021-2032)
- 7.3 Global GLP-1 Drug Peptide API Price by Type (2021-2032)
8 Segment by Application
- 8.1 Global GLP-1 Drug Peptide API Production by Application (2021-2032)
- 8.1.1 Global GLP-1 Drug Peptide API Production by Application (2021-2032) & (Tons)
- 8.1.2 Global GLP-1 Drug Peptide API Production Market Share by Application (2021-2032)
- 8.2 Global GLP-1 Drug Peptide API Production Value by Application (2021-2032)
- 8.2.1 Global GLP-1 Drug Peptide API Production Value by Application (2021-2032) & (US$ Million)
- 8.2.2 Global GLP-1 Drug Peptide API Production Value Market Share by Application (2021-2032)
- 8.3 Global GLP-1 Drug Peptide API Price by Application (2021-2032)
9 Value Chain and Sales Channels Analysis of the Market
- 9.1 GLP-1 Drug Peptide API Value Chain Analysis
- 9.1.1 GLP-1 Drug Peptide API Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 GLP-1 Drug Peptide API Production Mode & Process
- 9.2 GLP-1 Drug Peptide API Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 GLP-1 Drug Peptide API Distributors
- 9.2.3 GLP-1 Drug Peptide API Customers
10 Global GLP-1 Drug Peptide API Analyzing Market Dynamics
- 10.1 GLP-1 Drug Peptide API Industry Trends
- 10.2 GLP-1 Drug Peptide API Industry Drivers
- 10.3 GLP-1 Drug Peptide API Industry Opportunities and Challenges
- 10.4 GLP-1 Drug Peptide API Industry Restraints
11 Report Conclusion
12 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst